A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán.

Siegler Zsuzsa, Neuwirth Magdolna, Hegyi Márta, Paraicz Eva, Pálmafy Beatrix, Tegzes Andrea, P. Barsi, V. Karcagi, Claes Lieve, Jonghe De Peter, Herczegfalvi Agnes, A. Fogarasi

Research output: Article

3 Citations (Scopus)

Abstract

OBJECTIVE AND BACKGROUND: Severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) is a malignant epilepsy syndrome characterized by prolonged febrile hemiconvulsions or generalized seizures starting in the first year of life. Later on myoclonic, atypical absence, and complex partial seizures appear. When one of these seizure forms is lacking the syndrome of borderline SMEI (SMEB) is defined. Psychomotor delay resulting in mental retardation is observed during the second year of life. In most patients a de novo sodium channel alpha-1 subunit (SCN1A) mutation can be identified. By reviewing the clinical, laboratory, and neuroimaging data of our SMEI patients diagnosed between 2000 and 2008, we would like to share our experiences in this rare but challenging syndrome. Our results will facilitate the earlier and better diagnosis of Hungarian children with SMEI. PATIENTS AND METHODS: Clinical, EEG, MRI and DNA mutation data of 20 SMEI patients treated in the Bethesda Children's Hospital (Budapest) were reviewed. RESULTS: The first seizure appeared at age 6.3+/-3.0 months. At least one of the first two seizures were complex febrile seizures in 19/20 and unilateral seizures in 12/20 children. All children except for one showed hemiconvulsions at least once; all children had seizures lasting longer than 15 minutes. Eight of twenty patients had SMEB. DNA diagnostics identified an SCN1A mutation in 17 patients (6 missense, 4 nonsense, 4 frameshift, 2 splice site, 1 deletion) while 3 children had no mutation. CONCLUSION: Early diagnosis of SMEI is important for the avoiding unnecessary examinations and false therapies as well as for genetic counselling. Typical symptoms of SMEI are early and prolonged febrile hemiconvulsions with neurological symptoms, mental retardation and secondary seizure types later on. The presence of an SCN1A mutation supports the diagnosis. We propose the availability of molecular diagnostics and stiripentol therapy for SMEI children in Hungary

Original languageHungarian
Pages (from-to)402-408
Number of pages7
JournalIdeggyógyászati szemle
Volume61
Issue number11-12
Publication statusPublished - nov. 30 2008

Fingerprint

Myoclonic Epilepsy
Seizures
Mutation
Febrile Seizures
Intellectual Disability
NAV1.1 Voltage-Gated Sodium Channel
Early Diagnosis
Molecular Pathology
Hungary
DNA
Genetic Counseling
Neuroimaging
Electroencephalography
Epilepsy
Fever

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zsuzsa, S., Magdolna, N., Márta, H., Eva, P., Beatrix, P., Andrea, T., ... Fogarasi, A. (2008). A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán. Ideggyógyászati szemle, 61(11-12), 402-408.

A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán. / Zsuzsa, Siegler; Magdolna, Neuwirth; Márta, Hegyi; Eva, Paraicz; Beatrix, Pálmafy; Andrea, Tegzes; Barsi, P.; Karcagi, V.; Lieve, Claes; De Peter, Jonghe; Agnes, Herczegfalvi; Fogarasi, A.

In: Ideggyógyászati szemle, Vol. 61, No. 11-12, 30.11.2008, p. 402-408.

Research output: Article

Zsuzsa, S, Magdolna, N, Márta, H, Eva, P, Beatrix, P, Andrea, T, Barsi, P, Karcagi, V, Lieve, C, De Peter, J, Agnes, H & Fogarasi, A 2008, 'A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán.', Ideggyógyászati szemle, vol. 61, no. 11-12, pp. 402-408.
Zsuzsa S, Magdolna N, Márta H, Eva P, Beatrix P, Andrea T et al. A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán. Ideggyógyászati szemle. 2008 nov. 30;61(11-12):402-408.
Zsuzsa, Siegler ; Magdolna, Neuwirth ; Márta, Hegyi ; Eva, Paraicz ; Beatrix, Pálmafy ; Andrea, Tegzes ; Barsi, P. ; Karcagi, V. ; Lieve, Claes ; De Peter, Jonghe ; Agnes, Herczegfalvi ; Fogarasi, A. / A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán. In: Ideggyógyászati szemle. 2008 ; Vol. 61, No. 11-12. pp. 402-408.
@article{ace02f5e4054437999320da08b445f34,
title = "A dravet-szindr{\'o}ma klinikai es genetikai diagnosztik{\'a}j{\'a}r{\'o}l husz eset{\"u}nk kapcs{\'a}n.",
abstract = "OBJECTIVE AND BACKGROUND: Severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) is a malignant epilepsy syndrome characterized by prolonged febrile hemiconvulsions or generalized seizures starting in the first year of life. Later on myoclonic, atypical absence, and complex partial seizures appear. When one of these seizure forms is lacking the syndrome of borderline SMEI (SMEB) is defined. Psychomotor delay resulting in mental retardation is observed during the second year of life. In most patients a de novo sodium channel alpha-1 subunit (SCN1A) mutation can be identified. By reviewing the clinical, laboratory, and neuroimaging data of our SMEI patients diagnosed between 2000 and 2008, we would like to share our experiences in this rare but challenging syndrome. Our results will facilitate the earlier and better diagnosis of Hungarian children with SMEI. PATIENTS AND METHODS: Clinical, EEG, MRI and DNA mutation data of 20 SMEI patients treated in the Bethesda Children's Hospital (Budapest) were reviewed. RESULTS: The first seizure appeared at age 6.3+/-3.0 months. At least one of the first two seizures were complex febrile seizures in 19/20 and unilateral seizures in 12/20 children. All children except for one showed hemiconvulsions at least once; all children had seizures lasting longer than 15 minutes. Eight of twenty patients had SMEB. DNA diagnostics identified an SCN1A mutation in 17 patients (6 missense, 4 nonsense, 4 frameshift, 2 splice site, 1 deletion) while 3 children had no mutation. CONCLUSION: Early diagnosis of SMEI is important for the avoiding unnecessary examinations and false therapies as well as for genetic counselling. Typical symptoms of SMEI are early and prolonged febrile hemiconvulsions with neurological symptoms, mental retardation and secondary seizure types later on. The presence of an SCN1A mutation supports the diagnosis. We propose the availability of molecular diagnostics and stiripentol therapy for SMEI children in Hungary",
author = "Siegler Zsuzsa and Neuwirth Magdolna and Hegyi M{\'a}rta and Paraicz Eva and P{\'a}lmafy Beatrix and Tegzes Andrea and P. Barsi and V. Karcagi and Claes Lieve and {De Peter}, Jonghe and Herczegfalvi Agnes and A. Fogarasi",
year = "2008",
month = "11",
day = "30",
language = "Hungarian",
volume = "61",
pages = "402--408",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "11-12",

}

TY - JOUR

T1 - A dravet-szindróma klinikai es genetikai diagnosztikájáról husz esetünk kapcsán.

AU - Zsuzsa, Siegler

AU - Magdolna, Neuwirth

AU - Márta, Hegyi

AU - Eva, Paraicz

AU - Beatrix, Pálmafy

AU - Andrea, Tegzes

AU - Barsi, P.

AU - Karcagi, V.

AU - Lieve, Claes

AU - De Peter, Jonghe

AU - Agnes, Herczegfalvi

AU - Fogarasi, A.

PY - 2008/11/30

Y1 - 2008/11/30

N2 - OBJECTIVE AND BACKGROUND: Severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) is a malignant epilepsy syndrome characterized by prolonged febrile hemiconvulsions or generalized seizures starting in the first year of life. Later on myoclonic, atypical absence, and complex partial seizures appear. When one of these seizure forms is lacking the syndrome of borderline SMEI (SMEB) is defined. Psychomotor delay resulting in mental retardation is observed during the second year of life. In most patients a de novo sodium channel alpha-1 subunit (SCN1A) mutation can be identified. By reviewing the clinical, laboratory, and neuroimaging data of our SMEI patients diagnosed between 2000 and 2008, we would like to share our experiences in this rare but challenging syndrome. Our results will facilitate the earlier and better diagnosis of Hungarian children with SMEI. PATIENTS AND METHODS: Clinical, EEG, MRI and DNA mutation data of 20 SMEI patients treated in the Bethesda Children's Hospital (Budapest) were reviewed. RESULTS: The first seizure appeared at age 6.3+/-3.0 months. At least one of the first two seizures were complex febrile seizures in 19/20 and unilateral seizures in 12/20 children. All children except for one showed hemiconvulsions at least once; all children had seizures lasting longer than 15 minutes. Eight of twenty patients had SMEB. DNA diagnostics identified an SCN1A mutation in 17 patients (6 missense, 4 nonsense, 4 frameshift, 2 splice site, 1 deletion) while 3 children had no mutation. CONCLUSION: Early diagnosis of SMEI is important for the avoiding unnecessary examinations and false therapies as well as for genetic counselling. Typical symptoms of SMEI are early and prolonged febrile hemiconvulsions with neurological symptoms, mental retardation and secondary seizure types later on. The presence of an SCN1A mutation supports the diagnosis. We propose the availability of molecular diagnostics and stiripentol therapy for SMEI children in Hungary

AB - OBJECTIVE AND BACKGROUND: Severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) is a malignant epilepsy syndrome characterized by prolonged febrile hemiconvulsions or generalized seizures starting in the first year of life. Later on myoclonic, atypical absence, and complex partial seizures appear. When one of these seizure forms is lacking the syndrome of borderline SMEI (SMEB) is defined. Psychomotor delay resulting in mental retardation is observed during the second year of life. In most patients a de novo sodium channel alpha-1 subunit (SCN1A) mutation can be identified. By reviewing the clinical, laboratory, and neuroimaging data of our SMEI patients diagnosed between 2000 and 2008, we would like to share our experiences in this rare but challenging syndrome. Our results will facilitate the earlier and better diagnosis of Hungarian children with SMEI. PATIENTS AND METHODS: Clinical, EEG, MRI and DNA mutation data of 20 SMEI patients treated in the Bethesda Children's Hospital (Budapest) were reviewed. RESULTS: The first seizure appeared at age 6.3+/-3.0 months. At least one of the first two seizures were complex febrile seizures in 19/20 and unilateral seizures in 12/20 children. All children except for one showed hemiconvulsions at least once; all children had seizures lasting longer than 15 minutes. Eight of twenty patients had SMEB. DNA diagnostics identified an SCN1A mutation in 17 patients (6 missense, 4 nonsense, 4 frameshift, 2 splice site, 1 deletion) while 3 children had no mutation. CONCLUSION: Early diagnosis of SMEI is important for the avoiding unnecessary examinations and false therapies as well as for genetic counselling. Typical symptoms of SMEI are early and prolonged febrile hemiconvulsions with neurological symptoms, mental retardation and secondary seizure types later on. The presence of an SCN1A mutation supports the diagnosis. We propose the availability of molecular diagnostics and stiripentol therapy for SMEI children in Hungary

UR - http://www.scopus.com/inward/record.url?scp=58149332344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149332344&partnerID=8YFLogxK

M3 - Article

C2 - 19070316

AN - SCOPUS:58149332344

VL - 61

SP - 402

EP - 408

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 11-12

ER -